objectives for the trial are to evaluate the vaccine’s safety and the antibody and T-cell responses of participants in the study. Paul Radspinner, FluGen’s co-founder, president, and CEO, said his company aims to have safety and immune response data on the 96 participants by the end of the year.
—Investigators at the UW-Madison’s Morgridge Institute for Research and other departments at the school received a $4.4 million grant to develop a camera that can snap pictures around corners, the university said. The funding comes from the U.S. Defense Department’s Defense Advanced Research Projects Agency, or DARPA, which played a key role in the development of the Internet and other innovations. A team led by Morgridge imaging specialist Andreas Velten developed the technology for the camera, which involves bouncing photons through the atmosphere and using finely tuned sensors to recapture them and rebuild a 3D environment.
—Exact Sciences (NASDAQ: [[ticker:EXAS]]) reported financial results from the second quarter that handily beat analyst expectations, sending shares up more than 30 percent on the day. Madison-based Exact, whose flagship product is an at-home, stool-based test for colorectal cancer, also completed more tests during the three-month period ending June 30 (54,000) than the 48,000 tests CEO Kevin Conroy had projected his company would complete. Exact reiterated its projections for completed tests (240,000) and revenue (between $90 million and $100 million) in 2016.
—Milwaukee-based Looking Glass Investments raised $5 million for a new fund, BizTimes Media reported. The startup has developed underwriting technology and data management tools that can be used to find and evaluate loan seekers on peer-to-peer lending websites like Lending Club (NYSE: [[ticker:LC]]). According to an SEC filing, the latest financing came from a single investor. In December, Houston-based Main Street Capital Corporation purchased a minority stake in Looking Glass.
